Hyderabad: Hyderabad-based Bharat Biotech announced on Friday that the Lancet peer review has confirmed the effectiveness analysis of Bharat Biotech’s Covaxin.
According to data from phase three clinical trials, Covaxin shows 77.8 percent efficacy against symptomatic COVID-19.
“COVAXIN is the only COVID-19 vaccine to show efficacy data from phase III clinical trials against the delta variant at 65.2 percent, ”said the official statement issued by Bharat Biotech, referring to the study by the Lancet.
“Efficacy analysis shows that Covaxin is 77.8 percent effective against symptoms COVID-19, by evaluating 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group, ”reads the company’s statement.
It further said that Covaxin would be 93.4 percent effective against severe symptomatic COVID-19.
“Safety analysis shows that adverse events reported were similar to placebo, with 12 percent of the subjects experiencing well-known side effects and less than 0.5 percent of the subjects experiencing serious adverse events,” it said.
“Efficiency data show 63.6 percent protection against asymptomatic COVID-19, 65.2 percent protection against the SARS-CoV-2, B.1.617.2 Delta and 70.8 percent protection against all variants of SARS-CoV-2 virus, ”Bharat Biotech added.
Dr Krishna Ella, Chairman and Managing Director (CMD) of Bharat Biotech said: “The data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most published COVID-19 vaccines in the world, ”he said.
“I am delighted to see that the Phase III efficacy data has also been published in the Lancet. This in itself speaks highly of the strong position of Covaxin among other global forerunners COVID-19 vaccines, ”said Dr Balram Bhargava, Director-General of the Indian Council for Medical Research (ICMR).
“The bank-to-bed journey of Covaxin in less than 10 months demonstrates the tremendous power of ‘Atmanirbhar Bharat’ along with the Indian academy and industry to fight against the odds and cut a niche in the world community,” said Bhargava added.
Recently, the World Health Organization granted a list of emergency use to Covaxin, enabling countries to expedite their regulatory approval for the import and administration of doses. It has also received emergency use authorizations in several countries with applications underway in more than 50 countries worldwide, the statement said.
Source: Telangana Today